Creo Medical Group (LON:CREO) Sets New 1-Year Low – Here’s Why

Creo Medical Group PLC (LON:CREO) reached a new 52-week low on Tuesday . The stock traded as low as GBX 15.50 ($0.20) and last traded at GBX 15.61 ($0.20), with a volume of 734123 shares trading hands. The stock had previously closed at GBX 16 ($0.20).

Creo Medical Group Stock Down 0.9 %

The company has a quick ratio of 2.19, a current ratio of 3.24 and a debt-to-equity ratio of 29.96. The company has a market capitalization of £54.68 million, a P/E ratio of -251.92 and a beta of 0.86. The company has a 50-day moving average of GBX 19.59 and a two-hundred day moving average of GBX 27.49.

Insider Activity at Creo Medical Group

In related news, insider Richard John Rees acquired 98,000 shares of the stock in a transaction on Thursday, October 24th. The stock was acquired at an average price of GBX 20 ($0.25) per share, for a total transaction of £19,600 ($24,904.70). Also, insider Kevin Crofton acquired 2,916,666 shares of the stock in a transaction on Monday, October 21st. The shares were bought at an average price of GBX 24 ($0.30) per share, with a total value of £699,999.84 ($889,453.42). 22.43% of the stock is currently owned by corporate insiders.

About Creo Medical Group

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.